11 results on '"Yuta Orihara"'
Search Results
2. Clinical evaluation of anterior nasal cavity swab specimens by a rapid antigen test using a GLINE-2019-nCoV Ag Kit to diagnose COVID-19
- Author
-
Kana Ogane, Kazuo Imai, Yuta Orihara, Masahiro Kodana, Mariko Tezuka, Nanako Matsuzaki, Rina Takahashi, Shintaro Ichimura, Mieko Tokano, Jun Sakai, Norihito Tarumoto, Shigefumi Maesaki, and Maeda Takuya more...
- Subjects
Microbiology (medical) ,Infectious Diseases ,Pharmacology (medical) - Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Tumor-Specificity, Neurotoxicity, and Possible Involvement of the Nuclear Receptor Response Pathway of 4,6,8-Trimethyl Azulene Amide Derivatives
- Author
-
Kotone Naitoh, Yuta Orihara, Hiroshi Sakagami, Takumi Miura, Keitaro Satoh, Shigeru Amano, Kenjiro Bandow, Yosuke Iijima, Kota Kurosaki, Yoshihiro Uesawa, Masashi Hashimoto, and Hidetsugu Wakabayashi
- Subjects
Receptors, Cytoplasmic and Nuclear ,Antineoplastic Agents ,Apoptosis ,Azulenes ,Catalysis ,QASR ,Inorganic Chemistry ,Cell Line, Tumor ,tumor-specificity ,neurotoxicity ,caspase 3 ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Cell Proliferation ,Molecular Structure ,Organic Chemistry ,General Medicine ,hormone receptor ,4,6,8-trimethyl azulene amide ,oral cancer ,molecular shape ,cell cycle ,NFκB ,Amides ,Computer Science Applications ,Carcinoma, Squamous Cell ,Mouth Neoplasms ,Neurotoxicity Syndromes ,Drug Screening Assays, Antitumor - Abstract
Background: Very few papers covering the anticancer activity of azulenes have been reported, as compared with those of antibacterial and anti-inflammatory activity. This led us to investigate the antitumor potential of fifteen 4,6,8-trimethyl azulene amide derivatives against oral malignant cells. Methods: 4,6,8-Trimethyl azulene amide derivatives were newly synthesized. Anticancer activity was evaluated by tumor-specificity against four human oral squamous cell carcinoma (OSCC) cell lines over three normal oral cells. Neurotoxicity was evaluated by cytotoxicity against three neuronal cell lines over normal oral cells. Apoptosis induction was evaluated by Western blot and cell cycle analyses. Results: Among fifteen derivatives, compounds 7, 9, and 15 showed the highest anticancer activity, and relatively lower neurotoxicity than doxorubicin, 5-fluorouracil (5-FU), and melphalan. They induced the accumulation of a comparable amount of a subG1 population, but slightly lower extent of caspase activation, as compared with actinomycin D, used as an apoptosis inducer. The quantitative structure–activity relationship analysis suggests the significant correlation of tumor-specificity with a 3D shape of molecules, and possible involvement of inflammation and hormone receptor response pathways. Conclusions: Compounds 7 and 15 can be potential candidates of a lead compound for developing novel anticancer drugs., Licensee MDPI, Basel, Switzerland.This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). more...
- Published
- 2022
4. Evaluation of a high-speed but low-throughput RT-qPCR system for detection of SARS-CoV-2
- Author
-
Rieko Kawamura, K. Ogane, Shinichi Takeuchi, Shigefumi Maesaki, Takashi Murakami, Jun Sakai, R. Matsumura, Takuya Maeda, Kazuo Imai, Masahiro Kodana, Norihito Tarumoto, Yuta Orihara, N. Matsuzaki, and Toru Kawamura more...
- Subjects
Microbiology (medical) ,0303 health sciences ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,030306 microbiology ,business.industry ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,fungi ,virus diseases ,General Medicine ,Computational biology ,030501 epidemiology ,Medical care ,Rapid identification ,Reverse transcription polymerase chain reaction ,03 medical and health sciences ,Infectious Diseases ,Real-time polymerase chain reaction ,Medicine ,0305 other medical science ,business ,Throughput (business) - Abstract
With the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), a high-speed and convenient detection technology should be at the forefront of medical care worldwide. This study evaluated the usefulness of GeneSoC, a compact, high-speed reciprocal flow quantitative reverse transcription polymerase chain reaction system, for the detection of SARS-CoV-2. The results support the use of this system for the rapid identification of SARS-CoV-2. This approach can contribute to the strategic selection of initial management strategies for patients with COVID-19. more...
- Published
- 2020
- Full Text
- View/download PDF
5. Matrix-Assisted Laser Desorption and Ionization Time-of-Flight Mass Spectrometry Analysis for the Direct Detection of SARS-CoV-2 in Nasopharyngeal Swabs
- Author
-
Tomoya Yoshinari, Katsuhiko Hayashi, Shouhei Hirose, Kenji Ohya, Takahiro Ohnishi, Maiko Watanabe, Satoshi Taharaguchi, Hirohisa Mekata, Takahide Taniguchi, Takuya Maeda, Yuta Orihara, Rieko Kawamura, Sakura Arai, Yoshiro Saito, Yukihiro Goda, and Yukiko Hara-Kudo more...
- Subjects
SARS-CoV-2 ,Lasers ,Nasopharynx ,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ,COVID-19 ,Humans ,RNA, Viral ,Analytical Chemistry ,Specimen Handling - Abstract
The most common diagnostic method used for coronavirus disease-2019 (COVID-19) is real-time reverse transcription polymerase chain reaction (PCR). However, it requires complex and labor-intensive procedures and involves excessive positive results derived from viral debris. We developed a method for the direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs, which uses matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-ToF MS) to identify specific peptides from the SARS-CoV-2 nucleocapsid phosphoprotein (NP). SARS-CoV-2 viral particles were separated from biological molecules in nasopharyngeal swabs by an ultrafiltration cartridge. Further purification was performed by an anion exchange resin, and purified NP was digested into peptides using trypsin. The peptides from SARS-CoV-2 that were inoculated into nasopharyngeal swabs were detected by MALDI-ToF MS, and the limit of detection was 10 more...
- Published
- 2022
6. Evaluation of a chemiluminescent enzyme immunoassay‐based high‐throughput SARS‐CoV‐2 antigen assay for the diagnosis of COVID‐19: The VITROS® SARS‐CoV‐2 Antigen Test
- Author
-
Rieko Kawamura, Masahiro Kodana, Nanako Matsuzaki, Norihito Tarumoto, Kazuo Imai, Shigefumi Maesaki, Masaru Matsuoka, Yuta Orihara, Shinichi Takeuchi, Yutaro Kitagawa, and Takuya Maeda
- Subjects
Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,Short Communication ,Short Communications ,Immunologic Tests ,Real-Time Polymerase Chain Reaction ,Sensitivity and Specificity ,SARS‐CoV‐2 ,law.invention ,COVID-19 Serological Testing ,Immunoenzyme Techniques ,03 medical and health sciences ,0302 clinical medicine ,COVID-19 Testing ,Antigen ,law ,COVID‐19 ,Virology ,Nasopharynx ,medicine ,Humans ,Mass Screening ,030212 general & internal medicine ,Antigens, Viral ,Mass screening ,Polymerase chain reaction ,Chemiluminescence ,medicine.diagnostic_test ,business.industry ,SARS-CoV-2 ,COVID-19 ,CLEIA ,Viral Load ,nasopharyngeal swab ,Infectious Diseases ,Immunoassay ,RNA, Viral ,030211 gastroenterology & hepatology ,business ,Viral load ,RT‐qPCR - Abstract
A high‐throughput, fully automated antigen detection test for SARS‐CoV‐2 is a viable alternative to reverse‐transcription polymerase chain reaction (RT‐qPCR) for mass screening during outbreaks. In this study, we compared RT‐qPCR for viral load and the VITROS® SARS‐CoV‐2 Antigen Test with reference to the results of the LUMIPULSE® SARS‐CoV‐2 Ag Test. Of 128 nasopharyngeal swab specimens taken from patients suspected of being infected with SARS‐CoV‐2, 49 were positive and 79 were negative according to RT‐qPCR. Consistent dose‐dependent detection with VITROS® assay was successfully achieved when using nasopharyngeal swab specimens with Ct values of 32.0 or lesser, whereas the CLEIA‐based LUMIPULSE® assay was able to detect lower viral loads compared with the VITROS® assay. Our results show that the performance of the VITROS® assay was satisfactory for the diagnosis of contagious COVID‐19 patients in the clinical setting. Highlights The performance of the VITROS® SARS‐CoV‐2 Antigen Test was sufficient for the diagnosis of contagious COVID‐19. This test showed high sensitivity and specificity in the detection of SARS‐CoV‐2 in samples with a Ct value of 32 or less. more...
- Published
- 2021
7. Evaluation of A Chemiluminescent Enzyme Immunoassay-Based High-Throughput SARS-CoV-2 Antigen Assay For The Diagnosis of COVID-19: The VITROS® SARS-CoV-2 Antigen Test
- Author
-
Nanako Matsuzaki, Yuta Orihara, Masahiro Kodana, Yutaro Kitagawa, Masaru Matsuoka, Rieko Kawamura, Shinichi Takeuchi, Kazuo Imai, Norihito Tarumoto, Shigefumi Maesaki, and Maeda Takuya
- Abstract
A high-throughput, fully automated antigen detection test for SARS-CoV-2 is a viable alternative to reverse transcription polymerase chain reaction (RT-qPCR) for mass screening during outbreaks. In this study, we compared RT-qPCR for viral load and the VITROS® SARS-CoV-2 Antigen Test with reference to the results of the LUMIPULSE® SARS-CoV-2 Ag Test. Of 128 nasopharyngeal swab specimens taken from patients suspected of being infected with SARS-CoV-2, 49 were positive and 79 were negative according to RT-qPCR. Consistent dose-dependent detection with VITROS® assay was successfully achieved when using nasopharyngeal swab specimens with Ct values of ≤32.0, whereas the CLEIA-based the LUMIPULSE® assay was able to detect lower viral loads compared with the VITROS® assay. Our results show that the performance of the VITROS® assay was satisfactory for the diagnosis of contagious COVID-19 patients in the clinical setting. more...
- Published
- 2021
- Full Text
- View/download PDF
8. Presepsin as a predictive biomarker of severity in COVID-19: A case series
- Author
-
Takuya Maeda, Jun Sakai, Masaru Matsuoka, Ai Fukada, Shinichi Takeuchi, Rieko Kawamura, Yutaro Kitagawa, Yuta Orihara, Shigefumi Maesaki, Norihito Tarumoto, and Kazuo Imai
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Respiratory rate ,Hemoglobin oxygen saturation ,Lipopolysaccharide Receptors ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Virology ,Medicine ,Humans ,030212 general & internal medicine ,Letter to the Editor ,Predictive biomarker ,Retrospective Studies ,biology ,business.industry ,SARS-CoV-2 ,C-reactive protein ,Mucin-1 ,COVID-19 ,Retrospective cohort study ,Oxygenation ,respiratory system ,Peptide Fragments ,respiratory tract diseases ,Infectious Diseases ,C-Reactive Protein ,biology.protein ,030211 gastroenterology & hepatology ,business ,Biomarkers ,circulatory and respiratory physiology - Abstract
Guidelines for the diagnosis and treatment of the novel coronavirus disease 2019 (COVID‐19) present clear criteria, including respiratory rate, hemoglobin oxygen saturation (SaO2), and oxygenation indicator (PaO2/FiO2)1. This article is protected by copyright. All rights reserved. more...
- Published
- 2020
9. Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-mediated isothermal amplification
- Author
-
Jun Sakai, Yutaro Kitagawa, Yuta Orihara, Kazuo Imai, Shinichi Takeuchi, Norihito Tarumoto, Takuya Maeda, Masaru Matsuoka, Shigefumi Maesaki, and Rieko Kawamura
- Subjects
0301 basic medicine ,Time Factors ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030106 microbiology ,Pneumonia, Viral ,Loop-mediated isothermal amplification ,medicine.disease_cause ,Sensitivity and Specificity ,Article ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,COVID-19 Testing ,Japan ,LAMP ,Virology ,Complementary DNA ,Medicine ,Humans ,030212 general & internal medicine ,Pandemics ,Coronavirus ,Detection limit ,business.industry ,Clinical Laboratory Techniques ,SARS-CoV-2 ,RT-qPCR ,RNA ,COVID-19 ,Reverse transcriptase ,Infectious Diseases ,Molecular Diagnostic Techniques ,business ,Coronavirus Infections ,Nucleic Acid Amplification Techniques - Abstract
Highlights • RT-LAMP test kits have good utility. • Detection sensitivity of 1.0 × 101 copies/μL can be obtained within 35 min. • RT-LAMP can be used as a point-of-care test because it is judged by turbidity under natural light., With the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for more rapid and simple detection technologies at the forefront of medical care worldwide. In this study, we evaluated the effectiveness of the Loopamp® 2019-SARSCoV-2 Detection Reagent Kit, which uses loop-mediated isothermal amplification (LAMP) technology. In this protocol, cDNA is synthesized from SARS-CoV-2 RNA using reverse transcriptase, followed by DNA amplification under isothermal conditions in one step. The RT-LAMP test kit amplified the targeted RNA of a SARS-CoV-2 isolate with a detection limit of 1.0 × 101 copies/μL, which was comparable to the detection sensitivity of quantitative reverse transcription PCR (RT-qPCR). Comparison with the results of RT-qPCR for 76 nasopharyngeal swab samples from patients with suspected COVID-19 showed a sensitivity of 100% and a specificity of 97.6%. In the 24 RNA specimens derived from febrile Japanese patients with or without influenza A, no amplification was observed using RT-LAMP. RT-LAMP could be a simple and easy-to-use diagnostic tool for the detection of SARS-CoV-2. more...
- Published
- 2020
10. Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays
- Author
-
Takuya Maeda, Shinichi Takeuchi, Norihito Tarumoto, Jun Sakai, Rieko Kawamura, Masaru Matsuoka, Kazuo Imai, Shigefumi Maesaki, Katsumi Kubota, Noriomi Ishibashi, Yutaro Kitagawa, and Yuta Orihara
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,030106 microbiology ,ECLIA ,Antibodies, Viral ,Sensitivity and Specificity ,Antibodies ,COVID-19 Serological Testing ,03 medical and health sciences ,0302 clinical medicine ,High-Throughput Screening Assays ,Medicine ,Humans ,SARS-cov-2 ,In patient ,030212 general & internal medicine ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,Immunoassay ,medicine.diagnostic_test ,biology ,business.industry ,fungi ,virus diseases ,COVID-19 ,General Medicine ,Middle Aged ,body regions ,Kinetics ,Infectious Diseases ,Antibody response ,Immunology ,biology.protein ,Female ,Original Article ,Antibody ,CLIA ,business ,Clinical evaluation - Abstract
Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2: the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required. more...
- Published
- 2021
11. Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene
- Author
-
Nobuhiko Haga, Takenobu Katagiri, Yuta Orihara, Sho Tsukamoto, Rieko Kawamura, Masaru Matsuoka, Mai Kuratani, and Kenji Ikebuchi
- Subjects
0301 basic medicine ,Heterozygote ,Histology ,Physiology ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Biology ,ACVR1 ,medicine.disease_cause ,DNA sequencing ,03 medical and health sciences ,Heart disorder ,Exon ,0302 clinical medicine ,medicine ,Humans ,DNA Primers ,Genetics ,Mutation ,Reproducibility of Results ,Exons ,Sequence Analysis, DNA ,medicine.disease ,genomic DNA ,030104 developmental biology ,Myositis Ossificans ,ACVR1 Gene ,Fibrodysplasia ossificans progressiva ,Activin Receptors, Type I - Abstract
The human ACVR1 gene encodes a transmembrane protein consisting of 509 amino acids called activin A receptor, type I (ACVR1) or activin receptor-like kinase 2 (ALK2) and has nine coding exons. The ALK2 protein functions as a signaling receptor for ligands of the transforming growth factor-β family. In the human ACVR1 gene, approximately 20 types of heterozygotic mutations in the coding exons have been associated with congenital disorders and somatic cancer, such as fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma, diffuse idiopathic skeletal hyperostosis and some congenital heart disorders. In the present study, we designed primers for direct sequencing of the nine coding exons in the human ACVR1 gene. The reliability of the primers was examined by PCR and DNA sequencing using genomic DNA prepared from peripheral blood or swab samples of three patients with FOP who had different mutations in the ACVR1 gene. A single nucleotide heterozygotic mutation was identified in each genomic sample without additional mutations in other regions. Therefore, the primers designed for the nine coding exons of the ACVR1 gene could be useful for the genetic diagnosis of patients who may have disorders associated with mutations in the ACVR1 gene. more...
- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.